Skip to main content
Q

Quantumzyme Corp. — Investor Relations & Filings

Ticker · QTZM ISIN · US75955E2054 Professional, scientific and technical activities
Open in API
Filings indexed 8 across all filing types
Latest filing 2026-03-12 Regulatory Filings
Country US United States of America
Listing — QTZM

About Quantumzyme Corp.

https://www.quantumzymecorp.com

Quantumzyme Corp. is a biotransformation company that specializes in enzyme engineering and biocatalysis. It develops sustainable, enzyme-based solutions as alternatives to traditional chemical processes for industrial applications. The company utilizes a proprietary in silico platform that integrates quantum mechanics, molecular dynamics, and structural modeling to discover, design, and enhance enzyme activity and selectivity. This technology aims to simplify complex chemistry, reduce hazardous pollutants, and advance clean, green chemical manufacturing.

Recent filings

Filing Released Lang Actions
Quantum Genesis AI Corp. Issues Statement Regarding OTC Markets Caveat Emptor Designation
Regulatory Filings Classification · 95% confidence The document is a corporate press release issued by Quantum Genesis AI Corp. regarding a 'Caveat Emptor' designation placed on its securities by OTC Markets. It discusses the company's efforts to communicate with the regulator and address the designation. As this is a general regulatory announcement regarding the company's status and does not fit into specific categories like M&A, earnings, or legal proceedings, it is classified as a Regulatory Filing (RNS).
2026-03-12 English
Quantumzyme Research Published in the Journal of Molecular Graphics & Modelling Study Highlights In Silico Enzyme Engineering Approach for Sustainable Drug Manufacturing
Regulatory Filings Classification · 95% confidence The document is a corporate press release issued by Quantumzyme Corp. It primarily discusses the publication of a scientific research paper in a journal and provides an update on a pending corporate name change and ticker symbol update with FINRA. Since it does not fit into specific categories like financial reports, board changes, or shareholder voting, and serves as a general corporate announcement disseminated via a news service, it is classified as a Regulatory Filing (RNS).
2026-02-12 English
Quantumzyme Announces Strategic Capital Structure Initiative, Corporate Rebranding Update, and Planned 4-for-1 Forward Stock Split
Share Issue/Capital Change Classification · 95% confidence The document is a corporate press release announcing a strategic capital structure initiative, specifically a 4-for-1 forward stock split, and a corporate rebranding. According to the filing definitions, announcements regarding stock splits and capital changes fall under the 'Share Issue/Capital Change' (SHA) category. While it mentions a name change, the primary financial impact described is the capital structure adjustment.
2026-02-09 English
Quantumzyme Featured on Cover of RSC Sustainability for Research in Enzyme Engineering for Ibuprofen Synthesis
Regulatory Filings Classification · 95% confidence The document is a corporate press release announcing that the company's research was featured on the cover of a scientific journal ('RSC Sustainability'). It does not contain financial results, regulatory filings, or specific corporate actions defined in the other categories. As it is a general corporate news announcement that does not fit into the specific categories provided, it falls under the 'Regulatory Filings' (RNS) fallback category, which is used for general corporate news and announcements disseminated via regulatory news services.
2026-01-30 English
Quantumzyme to Attend 2026 BIO International Convention
Regulatory Filings Classification · 95% confidence The document is a corporate press release announcing that Quantumzyme Corp. plans to attend the 2026 BIO International Convention. It does not contain financial results, governance changes, or any other specific regulatory filing content defined in the other categories. As it is a general corporate announcement disseminated via a news service, it falls under the 'Regulatory Filings' (RNS) fallback category.
2026-01-28 English
Quantumzyme Announces Next-Generation Enzyme Engineering Platform for More Efficient Pharmaceutical Manufacturing
Regulatory Filings Classification · 95% confidence The document is a corporate press release announcing a technological advancement (a new enzyme engineering platform) by Quantumzyme Corp. It does not contain financial statements, regulatory filings, or specific shareholder meeting materials. As it is a general corporate news announcement disseminated via a news service (EQS), it falls under the 'Regulatory Filings' category as the fallback for miscellaneous corporate news that does not fit into more specific categories like Earnings Releases or M&A.
2026-01-27 English

Browse filings by year

1 year

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.